University of Pittsburgh

Cothera Bioscience, Inc.

Adastra Pharmaceuticals, Inc.

Thomas M Estok

Eckard Weber

Tracy Parrott

Sameer Agnihotri

Alberto Broniscer

Ian F Pollack

Tracy Lee Lawhon

The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.

Treatment of cancer with TG02

The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.

Use of TG02 for treating gliomas in pediatric subjects

Growing community of inventors

Lakewood Ranch, FL, United States of America

Thomas M Estok